The calculation workspace
GLP-1 Weight Loss Timeline
See how published clinical-trial average weight-loss curves map onto a starting weight across major GLP-1 and dual/triple-agonist studies.
Every endpoint comes from a peer-reviewed trial (STEP 1, STEP UP, SURMOUNT-1, SUSTAIN FORTE, SURPASS-2, SCALE, and TRIUMPH-1). Trial means describe study groups, not guaranteed individual outcomes.
1. Estimate Clinical Trial Weight Timeline
Investigational — not FDA approved
| Milestone | Modeled % change | Cumulative loss | Reference weight |
|---|
2. Published Trial Endpoints Side by Side
These trials differed in duration, baseline populations (with or without type 2 diabetes), and statistical estimands. Direct comparisons are valid only within head-to-head studies such as SURMOUNT-5 or SURPASS-2.
| Medication & Dose | Trial | Duration | Mean Weight Change | Placebo |
|---|---|---|---|---|
| Wegovy 2.4 mg | STEP 1 (no T2D) | 68 weeks | -14.9% | -2.4% |
| Wegovy 7.2 mg | STEP UP (no T2D) | 72 weeks | -18.7% | -3.9% |
| Zepbound 5 / 10 / 15 mg | SURMOUNT-1 (no T2D) | 72 weeks | -15.0% / -19.5% / -20.9% | -3.1% |
| Ozempic 2 mg | SUSTAIN FORTE (T2D) | 40 weeks | ~-7.0% (~6.9 kg) | Active comparator |
| Mounjaro 15 mg | SURPASS-2 (T2D) | 40 weeks | ~-12.0% (11.2 kg) | Active comparator |
| Saxenda 3.0 mg | SCALE (no T2D) | 56 weeks | -8.0% | -2.6% |
| Orforglipron 45 mg | Phase 2 (no T2D) | 36 weeks | -14.7% | -2.3% |
| Retatrutide 12 mg (investigational) | TRIUMPH-1 ITT | 80 weeks | -25.0% | -2.1% |
3. Preserving Lean Mass While Tracking Progress
Weight on the scale combines fat mass and lean mass. Clinical body-composition sub-studies show that roughly 25% to 40% of weight lost during rapid calorie restriction can come from lean tissue unless paired with adequate protein and resistance exercise. Read GLP-1 and Muscle Loss for the clinical evidence on body composition during treatment.
5. Weight Loss Timeline FAQ
How much weight do people lose on Wegovy vs Zepbound in clinical trials?
In separate 68- to 72-week trials of adults with obesity and no diabetes, Wegovy 2.4 mg averaged 14.9% weight loss (STEP 1) and Wegovy 7.2 mg averaged 18.7% (STEP UP), while Zepbound averaged 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg (SURMOUNT-1). In the open-label head-to-head SURMOUNT-5 trial, tirzepatide (10–15 mg) averaged 20.2% vs 13.7% for semaglutide (1.7–2.4 mg).
Why is average weight loss smaller in Ozempic and Mounjaro trials?
Ozempic and Mounjaro trials (such as SUSTAIN FORTE and SURPASS-2) enrolled adults with type 2 diabetes and ran for 40 weeks rather than 68–72 weeks. Across GLP-1 trials, participants with type 2 diabetes consistently lose less weight on average than participants without diabetes.
Is this calculator a personal prediction of how much weight I will lose?
No. Every curve reflects a published group average from a specific clinical trial that included structured nutrition and physical-activity counseling. Individual responses range widely — some people lose more than the mean, while others lose less or discontinue due to side effects.
Why does the curve slow down over time?
In virtually every incretin trial, weight loss is steepest during the first 6 to 9 months as doses escalate and energy intake drops, then gradually flattens into a plateau around 12 to 18 months as resting energy expenditure adjusts to a lower body mass.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational Eli Lilly triple agonist (GIP, GLP-1, and glucagon). Its Phase 2 and TRIUMPH-1 Phase 3 results are shown strictly as published research data, not an approved treatment.